Order Article Reprints

De Cicco M, Lagreca I, Basso S, Barozzi P, Muscianisi S, Bianco A, Riva G, Di Vincenzo S, Pulvirenti C, Sapuppo D, et al. Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1^mut) for the Treatment of NPM1^mut-Acute Myeloid Leukemia. Cancers. 2023; 15(10):2731. https://doi.org/10.3390/cancers15102731

De Cicco, Marica, Ivana Lagreca, Sabrina Basso, Patrizia Barozzi, Stella Muscianisi, Alba Bianco, Giovanni Riva, Sara Di Vincenzo, Chiara Pulvirenti, Davide Sapuppo, and et al. 2023. "Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1^mut) for the Treatment of NPM1^mut-Acute Myeloid Leukemia" Cancers 15, no. 10: 2731. https://doi.org/10.3390/cancers15102731

De Cicco, M., Lagreca, I., Basso, S., Barozzi, P., Muscianisi, S., Bianco, A., Riva, G., Di Vincenzo, S., Pulvirenti, C., Sapuppo, D., Siciliano, M., Rosti, V., Candoni, A., Zecca, M., Forghieri, F., Luppi, M., & Comoli, P. (2023). Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1^mut) for the Treatment of NPM1^mut-Acute Myeloid Leukemia. Cancers, 15(10), 2731. https://doi.org/10.3390/cancers15102731